BRPI0820564A2 - método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco - Google Patents
método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíacoInfo
- Publication number
- BRPI0820564A2 BRPI0820564A2 BRPI0820564A BRPI0820564A BRPI0820564A2 BR PI0820564 A2 BRPI0820564 A2 BR PI0820564A2 BR PI0820564 A BRPI0820564 A BR PI0820564A BR PI0820564 A BRPI0820564 A BR PI0820564A BR PI0820564 A2 BRPI0820564 A2 BR PI0820564A2
- Authority
- BR
- Brazil
- Prior art keywords
- likelihood
- determining
- therapeutic response
- cancer chemotherapy
- cardiac glycoside
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01003—Adenosine triphosphatase (3.6.1.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98750107P | 2007-11-13 | 2007-11-13 | |
PCT/US2008/082641 WO2009064657A1 (en) | 2007-11-13 | 2008-11-06 | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0820564A2 true BRPI0820564A2 (pt) | 2017-05-23 |
Family
ID=40639083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0820564A BRPI0820564A2 (pt) | 2007-11-13 | 2008-11-06 | método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco |
Country Status (12)
Country | Link |
---|---|
US (4) | US8367363B2 (pt) |
EP (1) | EP2231165B1 (pt) |
JP (1) | JP5358583B2 (pt) |
KR (1) | KR101556805B1 (pt) |
CN (1) | CN101909637B (pt) |
AU (1) | AU2008321225B2 (pt) |
BR (1) | BRPI0820564A2 (pt) |
CA (1) | CA2705272C (pt) |
ES (1) | ES2414057T3 (pt) |
MX (1) | MX2010005081A (pt) |
RU (2) | RU2571687C2 (pt) |
WO (1) | WO2009064657A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200538738A (en) | 2004-02-20 | 2005-12-01 | Univ California | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity |
ES2414057T3 (es) | 2007-11-13 | 2013-07-18 | Phoenix Biotechnology Inc. | Método para determinar la probabilidad de una respuesta terapéutica en la quimioterapia de cáncer con glicósido cardiaco |
US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
US10383886B2 (en) | 2010-01-11 | 2019-08-20 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with oleandrin |
US10307450B2 (en) | 2010-01-11 | 2019-06-04 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
BR112012017073A2 (pt) | 2010-01-11 | 2015-09-01 | Phoenix Biotechnology Inc | Método de tratamento de condições neurológicas com glicosídeos cardíacos |
WO2012071152A2 (en) * | 2010-11-22 | 2012-05-31 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of nerium species or thevetia species |
CN101869574B (zh) * | 2010-07-24 | 2011-12-21 | 南京大学 | 哇巴因在增强非小细胞肺癌细胞敏感性中的应用 |
US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
US8541382B2 (en) | 2010-11-13 | 2013-09-24 | Sirbal Ltd. | Cardiac glycoside analogs in combination with emodin for cancer therapy |
US10386371B2 (en) | 2011-09-08 | 2019-08-20 | The Regents Of The University Of California | Metabolic flux measurement, imaging and microscopy |
US20140353486A1 (en) | 2011-12-07 | 2014-12-04 | Glaxosmithkline Llc | Methods for determining total body skeletal muscle mass |
US9561245B2 (en) | 2012-09-06 | 2017-02-07 | The Board Of Regents Of The University Of Texas System | Combination treatments for melanoma |
US9134319B2 (en) | 2013-03-15 | 2015-09-15 | The Regents Of The University Of California | Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo |
US10841741B2 (en) | 2015-07-07 | 2020-11-17 | Crowdcomfort, Inc. | Systems and methods for providing error correction and management in a mobile-based crowdsourcing platform |
US9625922B2 (en) | 2013-07-10 | 2017-04-18 | Crowdcomfort, Inc. | System and method for crowd-sourced environmental system control and maintenance |
US10379551B2 (en) | 2013-07-10 | 2019-08-13 | Crowdcomfort, Inc. | Systems and methods for providing augmented reality-like interface for the management and maintenance of building systems |
US11394462B2 (en) | 2013-07-10 | 2022-07-19 | Crowdcomfort, Inc. | Systems and methods for collecting, managing, and leveraging crowdsourced data |
US10070280B2 (en) | 2016-02-12 | 2018-09-04 | Crowdcomfort, Inc. | Systems and methods for leveraging text messages in a mobile-based crowdsourcing platform |
US10796085B2 (en) | 2013-07-10 | 2020-10-06 | Crowdcomfort, Inc. | Systems and methods for providing cross-device native functionality in a mobile-based crowdsourcing platform |
US10541751B2 (en) | 2015-11-18 | 2020-01-21 | Crowdcomfort, Inc. | Systems and methods for providing geolocation services in a mobile-based crowdsourcing platform |
US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
EP3047277B1 (en) | 2013-09-18 | 2018-11-21 | Adelaide Research & Innovation Pty Ltd. | Autoantibody biomarkers of ovarian cancer |
WO2015142117A1 (ko) * | 2014-03-20 | 2015-09-24 | 숙명여자대학교산학협력단 | 강심 배당체를 이용한 stk11-돌연변이 암 치료용 약학적 조성물 |
CN104502469A (zh) * | 2014-12-02 | 2015-04-08 | 长春远大国奥制药有限公司 | 一种安替可胶囊的含量测定方法 |
US10715653B2 (en) * | 2015-07-07 | 2020-07-14 | Crowdcomfort, Inc. | Systems and methods for providing geolocation services |
JP6841609B2 (ja) | 2015-07-10 | 2021-03-10 | 3スキャン インコーポレイテッド | 組織学的染色の空間的多重化 |
ITUB20159141A1 (it) * | 2015-12-22 | 2017-06-22 | Univ Degli Studi Di Roma La Sapienza 00185 Roma / It | Trattamento del tumore cerebrale |
AU2017205749B2 (en) * | 2016-01-08 | 2021-12-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
RU2623143C1 (ru) * | 2016-06-03 | 2017-06-22 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ комплексной оценки эффективности полихимиотерапии у больных с рецидивной лимфомой Ходжкина |
WO2018053123A1 (en) | 2016-09-14 | 2018-03-22 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
US10596186B2 (en) | 2016-09-14 | 2020-03-24 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infections |
US10729735B1 (en) | 2016-09-14 | 2020-08-04 | Phoenix Biotechnology, Inc. | Method and compostitions for treating coronavirus infection |
US10702567B2 (en) | 2016-09-14 | 2020-07-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
CN107065518B (zh) * | 2016-11-28 | 2019-12-24 | 国网浙江省电力公司电力科学研究院 | 一种超临界机组协调预测函数控制算法 |
US20210147796A1 (en) * | 2017-06-07 | 2021-05-20 | Academia Sinica | Method for removing undifferentiated pluripotent stem cells |
CN107478649A (zh) * | 2017-09-04 | 2017-12-15 | 中国热带农业科学院热带作物品种资源研究所 | 苯酚类化合物作为甲型强心苷显色剂的用途及甲型强心苷含量的测定方法 |
US11331291B2 (en) | 2017-09-14 | 2022-05-17 | Phoenix Biotechnology, Inc. | Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders |
CA3075023A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | Method and improved neuroprotective composition for treating neurological conditions |
MX2020002883A (es) | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composiciones para tratar la infección viral. |
US20220062317A1 (en) * | 2018-12-20 | 2022-03-03 | Universität Basel | Na+/k+ atpase inhibitors for use in the prevention or treatment of metastasis |
WO2021054978A1 (en) * | 2019-09-20 | 2021-03-25 | Pollard Bette Silver | Cardiac cardenolides to reduce fibrosis and enhance epithelial differentiation |
EP4069253A4 (en) * | 2019-12-02 | 2024-01-10 | Phoenix Biotechnology, Inc. | METHOD AND COMPOSITIONS FOR TREATING GLIOBLASTOMA |
MX2020009095A (es) | 2020-03-31 | 2022-07-28 | Phoenix Biotechnology Inc | Metodo y composiciones para el tratamiento de infeccion por coronavirus. |
EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
US12097234B2 (en) | 2020-05-24 | 2024-09-24 | Phoenix Biotechnology, Inc. | Extract containing oleandrin and method of production thereof |
US20230372458A1 (en) | 2020-08-21 | 2023-11-23 | Alexandre Vasilievich Ivachtchenko | Antiviral agent for combined therapy of covid-19 (sars-cov-2) |
CN115006418B (zh) * | 2022-05-13 | 2024-03-05 | 暨南大学 | 地高辛在制备抑制结直肠癌转移的药物中的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US5872103A (en) | 1986-11-26 | 1999-02-16 | Belletti; Dino A. | Prevention of mammary tumors by treatment with cardiac glycosides |
US6159702A (en) * | 1995-07-31 | 2000-12-12 | Boston University | In-vitro diagnostic method for determining whether a primary breast tumor is clinically metastatic |
US5891855A (en) | 1996-02-12 | 1999-04-06 | The Scripps Research Institute | Inhibitors of leaderless protein export |
US6300311B1 (en) * | 1998-04-14 | 2001-10-09 | Texas Tech University | Regulation of vertebrate ovarian maturation and function using growth factors |
JP2002523104A (ja) * | 1998-08-26 | 2002-07-30 | ババリアン・ノルディック・リサーチ・インスティテュート・アクティーゼルスカブ | 細胞増殖阻害剤および細胞分化の段階を判定する分子マーカーとしての、グアニル酸結合タンパク質(gbp−1) |
ATE234114T1 (de) * | 1999-01-15 | 2003-03-15 | Light Sciences Corp | Therapeutische zusammensetzungen fur knochenstoffwechselstörungen oder knochenmetastasen enthaltend einen photosensitizer und ein bisphosphonat |
US6835715B1 (en) * | 1999-02-12 | 2004-12-28 | University Of Louisville Research Foundation, Inc. | Mammalian dihydroouabain-like factor and therapeutic compositions |
US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
US20080081037A1 (en) * | 2002-12-23 | 2008-04-03 | Johannes Grosse | Methods and Agents for Diagnosis and Prevention, Amelioration or Treatment of Goblet Cell-Related Disorders |
US8178302B2 (en) * | 2003-07-21 | 2012-05-15 | Cernetics, Llc. | Mouse models for studying and treating hepatocellular and gastrointestinal tumors |
JP5033420B2 (ja) * | 2003-09-15 | 2012-09-26 | リサーチ ディベロップメント ファウンデーション | アクチビン及びTGF−bのシグナリングのCriptoによる拮抗方法 |
EP1789090A2 (en) * | 2004-09-02 | 2007-05-30 | Bionaut Pharmaceuticals, Inc. | Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors |
US20060205679A1 (en) * | 2004-10-22 | 2006-09-14 | Azaya Therapeutics, Inc. | Topical and oral formulations of cardiac glycosides for treating skin diseases |
US20060160112A1 (en) * | 2004-12-02 | 2006-07-20 | Erdal Cavusoglu | Tissue inhibitor of metalloproteinase (TIMP) as a marker and predictor of cardiovascular disease and both cardiac and non-cardiac mortality |
US7402325B2 (en) * | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
JP2009504782A (ja) * | 2005-08-18 | 2009-02-05 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 神経疾患を治療するための方法および組成物 |
JP2009518314A (ja) * | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法 |
EP1977246B1 (en) * | 2005-12-30 | 2010-01-20 | Ventana Medical Systems, Inc. | Na+, k+-atpase expression in cervical dysplasia and cancer |
ES2414057T3 (es) | 2007-11-13 | 2013-07-18 | Phoenix Biotechnology Inc. | Método para determinar la probabilidad de una respuesta terapéutica en la quimioterapia de cáncer con glicósido cardiaco |
-
2008
- 2008-11-06 ES ES08850574T patent/ES2414057T3/es active Active
- 2008-11-06 RU RU2013151251/15A patent/RU2571687C2/ru active
- 2008-11-06 CN CN2008801236156A patent/CN101909637B/zh active Active
- 2008-11-06 RU RU2010123795/15A patent/RU2508114C2/ru active
- 2008-11-06 AU AU2008321225A patent/AU2008321225B2/en active Active
- 2008-11-06 CA CA2705272A patent/CA2705272C/en active Active
- 2008-11-06 KR KR1020107011478A patent/KR101556805B1/ko active IP Right Grant
- 2008-11-06 EP EP08850574.8A patent/EP2231165B1/en active Active
- 2008-11-06 WO PCT/US2008/082641 patent/WO2009064657A1/en active Application Filing
- 2008-11-06 MX MX2010005081A patent/MX2010005081A/es active IP Right Grant
- 2008-11-06 JP JP2010534103A patent/JP5358583B2/ja active Active
- 2008-11-06 BR BRPI0820564A patent/BRPI0820564A2/pt not_active Application Discontinuation
-
2010
- 2010-05-04 US US12/773,540 patent/US8367363B2/en active Active
-
2013
- 2013-01-30 US US13/754,593 patent/US20130324485A1/en not_active Abandoned
-
2015
- 2015-04-29 US US14/699,595 patent/US9494589B2/en active Active
-
2016
- 2016-10-21 US US15/299,627 patent/US9846156B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2508114C2 (ru) | 2014-02-27 |
US9494589B2 (en) | 2016-11-15 |
WO2009064657A1 (en) | 2009-05-22 |
AU2008321225B2 (en) | 2013-08-01 |
US8367363B2 (en) | 2013-02-05 |
AU2008321225A1 (en) | 2009-05-22 |
CA2705272C (en) | 2020-05-12 |
RU2013151251A (ru) | 2015-05-27 |
RU2571687C2 (ru) | 2015-12-20 |
KR20100087730A (ko) | 2010-08-05 |
KR101556805B1 (ko) | 2015-10-01 |
EP2231165A4 (en) | 2010-12-15 |
JP2011508184A (ja) | 2011-03-10 |
ES2414057T3 (es) | 2013-07-18 |
RU2010123795A (ru) | 2011-12-20 |
US20100317541A1 (en) | 2010-12-16 |
US9846156B2 (en) | 2017-12-19 |
CA2705272A1 (en) | 2009-05-22 |
CN101909637A (zh) | 2010-12-08 |
US20130324485A1 (en) | 2013-12-05 |
EP2231165B1 (en) | 2013-05-15 |
JP5358583B2 (ja) | 2013-12-04 |
US20170067897A1 (en) | 2017-03-09 |
CN101909637B (zh) | 2013-09-18 |
MX2010005081A (es) | 2010-06-23 |
US20150316550A1 (en) | 2015-11-05 |
EP2231165A1 (en) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0820564A2 (pt) | método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco | |
BRPI0814135A2 (pt) | Prótese para mama cheia com gel elastomérico com barreira total | |
EP2214518A4 (en) | METABOLIC IMPROVEMENT TREATMENT | |
BRPI0821145A2 (pt) | Agente terapêutico para prurido | |
NO20062108L (no) | Brystsimulator | |
DK2144905T3 (da) | Terapeutiske midler | |
HK1151972A1 (en) | Resuscitation fluid | |
EP2164505A4 (en) | TREATMENT OF CHRONIC LUNG DISEASE | |
BRPI0811134A2 (pt) | Método para reduzir cardiotoxicidade e/ou melhorar a sobrevivência de quimioterapia com antraciclina, e, composição farmacêutica | |
BRPI0813789A2 (pt) | Potenciação de quimioterapia contra câncer | |
BRPI0812040A2 (pt) | Indicações para terapia de anti-il-i-beta | |
BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
FI20065708A0 (fi) | Laitteisto yksillöllisesti muotoiltujen jalkineiden suunnittelemiseksi | |
BRPI0810384A2 (pt) | Terapia enzimática anticâncer | |
BRPI1009448A2 (pt) | combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos | |
BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
DE502008002855D1 (de) | Fördereinheit | |
GB0700645D0 (en) | Targets for disease therapy | |
BRPI0812924A2 (pt) | Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos | |
EP2167132A4 (en) | LIQUID OF RESUSCITATION | |
BRPI0815772A2 (pt) | Tratamento de câncer de pulmão | |
IS8660A (is) | Gliklasíð lyfjasamsetning | |
GB0700647D0 (en) | Targets for disease therapy | |
GB0700646D0 (en) | Targets for disease therapy | |
GB0700648D0 (en) | Targets for disease therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |